RNA transfection

aTyr Pharma Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Giovedì, Febbraio 9, 2023

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the pricing of its previously announced underwritten public offering of 22,225,000 shares of its common stock at a public offering price of $2.25 per share.

Key Points: 
  • SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the pricing of its previously announced underwritten public offering of 22,225,000 shares of its common stock at a public offering price of $2.25 per share.
  • The gross proceeds to aTyr from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $50.0 million.
  • In addition, aTyr has granted the underwriters a 30-day option to purchase up to an additional 3,333,750 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
  • All of the shares being sold in the offering are being sold by aTyr.

aTyr Pharma Announces Commencement of Public Offering of Common Stock

Retrieved on: 
Mercoledì, Febbraio 8, 2023

In addition, aTyr expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to an additional 15% of the shares sold in the public offering.

Key Points: 
  • In addition, aTyr expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to an additional 15% of the shares sold in the public offering.
  • All of the shares to be sold in the offering are to be sold by aTyr.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
  • These forward-looking statements include statements regarding the timing, terms and completion of the proposed public offering and anticipated use of proceeds from the offering.

Evaxion and Pantherna announce promising preclinical mRNA vaccine data

Retrieved on: 
Mercoledì, Febbraio 8, 2023

The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model when delivered using Pantherna’s proprietary lipid nanoparticle mRNA platform (PTXΔLNP®, PTXmRNA®).

Key Points: 
  • The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model when delivered using Pantherna’s proprietary lipid nanoparticle mRNA platform (PTXΔLNP®, PTXmRNA®).
  • “We are extremely pleased with the preclinical data that clearly demonstrate the potential for our combined technologies.
  • The data provide further evidence that immunogenic sequences identified by Evaxion’s AI platforms are able to drive a relevant immune response on multiple vaccine platforms, including mRNA.
  • In continuation of these positive findings, Evaxion and Pantherna will further explore optimal LNP formulations to effectively deliver mRNA and DNA-encoded antigens identified by Evaxion’s AI platforms.

aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd.

Retrieved on: 
Lunedì, Febbraio 6, 2023

SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that its partner Kyorin Pharmaceutical Co., Ltd. (Kyorin), a wholly owned subsidiary of Kyorin Holdings, Inc., has dosed the first patient in Japan in EFZO-FIT™, a global pivotal Phase 3 study to evaluate the efficacy and safety of the Company’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD). This achievement has triggered a $10 million milestone payment by Kyorin to aTyr pursuant to a collaboration and license agreement between the Company and Kyorin.

Key Points: 
  • This achievement has triggered a $10 million milestone payment by Kyorin to aTyr pursuant to a collaboration and license agreement between the Company and Kyorin.
  • Efzofitimod is a first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory diseases states via selective modulation of neuropilin-2 (NRP2).
  • Kyorin has the exclusive rights to develop and commercialize efzofitimod in Japan for all forms of ILD.
  • The study intends to enroll 264 subjects with pulmonary sarcoidosis at multiple centers in the United States, Europe and Japan.

BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility

Retrieved on: 
Giovedì, Febbraio 2, 2023

Plasmid DNA is an important starting material for the manufacturing of mRNA-based vaccines and therapies, as well as cell therapies.

Key Points: 
  • Plasmid DNA is an important starting material for the manufacturing of mRNA-based vaccines and therapies, as well as cell therapies.
  • With the new facility, BioNTech plans to independently manufacture plasmid DNA for clinical product candidates and commercial products in the areas of cancer and infectious diseases.
  • BioNTech plans to independently manufacture the majority of its own current regular demand for DNA plasmids in the new manufacturing facility, once it is operational and pending regulatory approvals.
  • The Company also expects the new manufacturing facility to enable faster production cycles and shorter delivery times for plasmid DNA for a number of clinical product candidates and commercial products.

GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate

Retrieved on: 
Mercoledì, Febbraio 1, 2023

The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda.

Key Points: 
  • The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda.
  • This phase I/II clinical trial is the first step in GreenLight’s integrated strategy of bringing a universal Covid-19 mRNA vaccine to market globally.
  • GreenLight’s mRNA vaccine candidate, GLB-COV2-043, contains mRNA, encoding the SARS-CoV-2 full-length spike protein from the Wuhan strain, formulated in a lipid nanoparticle.
  • Pending positive safety and immunogenicity results from this Phase I/II clinical trial, GreenLight will look to continue development in Africa on potential next-generation Covid-19 vaccine candidates.

Providence Therapeutics Appoints Robert Georgantas, Ph.D. as President and Chief Technology Officer

Retrieved on: 
Mercoledì, Febbraio 1, 2023

CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today announced the appointment of Robert Georgantas III, Ph.D., as President and chief technology officer (CTO).

Key Points: 
  • CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today announced the appointment of Robert Georgantas III, Ph.D., as President and chief technology officer (CTO).
  • “Robert’s experience in drug discovery, clinical development, and management at the executive level across several biotech and large pharmaceutical companies will be invaluable as we continue advancing our pipeline of mRNA vaccines,” said Brad Sorenson, MBA, chief executive officer of Providence Therapeutics.
  • He additionally contributed to clinical development and medical affairs activities, participating in the design and statistical analysis of multiple clinical studies.
  • Dr. Georgantas received his Ph.D. at the Johns Hopkins University School of Medicine and his master’s degree in Cellular Biology at the Illinois Institute of Technology.

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

Retrieved on: 
Martedì, Gennaio 31, 2023

BOSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful preclinical proof-of-mechanism studies with its immunotherapy candidate, TTX-RIGA, in melanoma.

Key Points: 
  • BOSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful preclinical proof-of-mechanism studies with its immunotherapy candidate, TTX-RIGA, in melanoma.
  • This is expected to result in targeted activation of innate immunity in the tumor microenvironment.
  • TransCode believes that understanding how to recruit PRRs, such as RIG-I, in a tumor-selective manner is critical for its adoption in the clinic.
  • Similar immunotherapeutics of others have been shown to induce complete tumor regressions in animals and have triggered immunity against the tumor.

aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference

Retrieved on: 
Martedì, Gennaio 31, 2023

SAN DIEGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data on the mechanism of action (MOA) and exposure-efficacy analysis for its lead therapeutic candidate, efzofitimod, in an oral symposia presentation and poster session, respectively, at the American Thoracic Society (ATS) 2023 International Conference, which is scheduled to take place May 19 – 24 in Washington, DC.

Key Points: 
  • “These abstracts highlight the important data we continue to generate for efzofitimod and our clinical program in pulmonary sarcoidosis, a major form of interstitial lung disease with high unmet medical need,” said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr.
  • Additionally, an exposure-efficacy analysis of efzofitimod provides further confirmatory evidence of clinical proof-of-concept from our previous study.”
    Preliminary details of the presentations appear below.
  • Additional information regarding the presentations will be released closer to the date of the ATS conference.
  • Title: Efzofitimod, a Novel Immunomodulator for Pulmonary Sarcoidosis, Modulates Patient Inflammatory Responses Through Myeloid Cells

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Retrieved on: 
Lunedì, Gennaio 30, 2023

ET

Key Points: 
  • ET
    BEDMINSTER, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB, Matinas), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today is providing a business update on its ongoing programs and discussing its strategic outlook for 2023.
  • Our ongoing collaborations with BioNTech and, recently, National Resilience, have aligned Matinas with two of the world’s leading companies in the gene therapy space.
  • The Company will host a live conference call and webcast to discuss this corporate update and 2023 business outlook today, Monday, January 30 at 4:30 p.m.
  • The live webcast will be accessible on the Investors section of Matinas BioPharma’s website, www.matinasbiopharma.com , and archived for 90 days.